The Potassium Transporting ATPase Alpha Chain 1 pipeline drugs market research report outlays comprehensive information on the Potassium Transporting ATPase Alpha Chain 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Potassium Transporting ATPase Alpha Chain 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Infectious Disease, Musculoskeletal Disorders, and Immunology which include the indications Reflux Esophagitis (Gastroesophageal Reflux Disease), Gastric Ulcers, Helicobacter pylori Infections, Osteoarthritis, and Rheumatoid Arthritis. It also reviews key players involved in Potassium Transporting ATPase Alpha Chain 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Potassium Transporting ATPase Alpha Chain 1 pipeline targets constitutes close to 24 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 6, 3, 6, 1, 3, and 1 respectively.
Potassium Transporting ATPase Alpha Chain 1 overview
Potassium-transporting ATPase alpha chain 1 (ATP4A) is a protein that generates a proton gradient across the gastric parietal cell membrane. This gradient acidifies gastric juice down to pH 1. The ATP1A1 gene encodes the alpha-1 subunit of a protein pump called Na+/K+ ATPase. This protein uses energy from adenosine triphosphate (ATP) to transport charged atoms (ions) into and out of cells.
For a complete picture of Potassium Transporting ATPase Alpha Chain 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
